PURPOSE: The aim of this study was to compare the safety and short-term efficacy of transcatheter arterial chemoembolization (TACE) using cisplatin-Lipiodol suspension (CP/Lp) with that using epirubicin-Lipiodol emulsion (EP/Lp) in patients with recurrent hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 28 HCC patients were enrolled prospectively and assigned to the CP/Lp group or EP/Lp group. Adverse effects related to TACE were graded; and the treatment effect (TE) on HCC nodules at 3 months and overall tumor response at 6 months were assessed as the endpoint. RESULTS: No significant difference was observed between the groups regarding the frequency of adverse effects of grade 3 or less. The TE rates for 100% necrosis plus >50% necrosis in 62 HCC nodules in the CP/Lp group and 75 HCC nodules in the EP/Lp group were 72.6% and 66.7%, respectively (P = 0.894). Overall tumor response revealed that six patients (50.0%) in the CP/Lp group and six patients (37.5%) in the EP/Lp group had a partial response plus a complete response, with no significant difference (P = 0.615). TACE-free control curves for both groups revealed no significant difference (P = 0.513). CONCLUSION: No significant difference was found with regard to adverse effects, the treatment effect on HCC nodules, or overall tumor response between the CP/Lp and EP/Lp groups.
RCT Entities:
PURPOSE: The aim of this study was to compare the safety and short-term efficacy of transcatheter arterial chemoembolization (TACE) using cisplatin-Lipiodol suspension (CP/Lp) with that using epirubicin-Lipiodol emulsion (EP/Lp) in patients with recurrent hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 28 HCC patients were enrolled prospectively and assigned to the CP/Lp group or EP/Lp group. Adverse effects related to TACE were graded; and the treatment effect (TE) on HCC nodules at 3 months and overall tumor response at 6 months were assessed as the endpoint. RESULTS: No significant difference was observed between the groups regarding the frequency of adverse effects of grade 3 or less. The TE rates for 100% necrosis plus >50% necrosis in 62 HCC nodules in the CP/Lp group and 75 HCC nodules in the EP/Lp group were 72.6% and 66.7%, respectively (P = 0.894). Overall tumor response revealed that six patients (50.0%) in the CP/Lp group and six patients (37.5%) in the EP/Lp group had a partial response plus a complete response, with no significant difference (P = 0.615). TACE-free control curves for both groups revealed no significant difference (P = 0.513). CONCLUSION: No significant difference was found with regard to adverse effects, the treatment effect on HCC nodules, or overall tumor response between the CP/Lp and EP/Lp groups.
Authors: H Kasugai; J Kojima; M Tatsuta; S Okuda; Y Sasaki; S Imaoka; M Fujita; S Ishiguro Journal: Gastroenterology Date: 1989-10 Impact factor: 22.682
Authors: K Kamada; T Nakanishi; M Kitamoto; H Aikata; Y Kawakami; K Ito; T Asahara; G Kajiyama Journal: J Vasc Interv Radiol Date: 2001-07 Impact factor: 3.464
Authors: Y Sasaki; S Imaoka; H Kasugai; M Fujita; S Kawamoto; S Ishiguro; J Kojima; O Ishikawa; H Ohigashi; H Furukawa Journal: Cancer Date: 1987-09-15 Impact factor: 6.860
Authors: G Fattovich; G Giustina; F Degos; F Tremolada; G Diodati; P Almasio; F Nevens; A Solinas; D Mura; J T Brouwer; H Thomas; C Njapoum; C Casarin; P Bonetti; P Fuschi; J Basho; A Tocco; A Bhalla; R Galassini; F Noventa; S W Schalm; G Realdi Journal: Gastroenterology Date: 1997-02 Impact factor: 22.682
Authors: K Nishimine; H Uchida; N Matsuo; H Sakaguchi; S Hirohashi; Y Nishimura; Q Guo; H Ohishi; N Nagano; T Yoshioka Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333